Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,160 | 1,250 | 11:23 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE CLINICAL TRIAL OF IMC-003/IMM72 | 4 | HKEx | ||
IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
16.06. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
09.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER | 1 | HKEx | ||
28.05. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
28.05. | IMMUNEONCO-B (01541): I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025; II. APPOINTMENT OF DIRECTOR | - | HKEx | ||
27.05. | IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
23.05. | Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago | 1 | GlobeNewswire (USA) | ||
22.05. | Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 ... | 220 | GlobeNewswire (Europe) | Phase 3 trial of '2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions Monotherapy US dose optimization Phase 1b/2... ► Artikel lesen | |
22.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM2510/AXN-2510 IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE NSCLC | - | HKEx | ||
14.05. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
14.05. | IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
07.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO FOR IMM2510 (PALVERAFUSP) ... | 1 | HKEx | ||
06.05. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF BUSINESS OFFICER | 1 | HKEx | ||
30.04. | IMMUNEONCO-B (01541): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 28, 2025 | - | HKEx | ||
30.04. | IMMUNEONCO-B (01541): NOTICE OF THE ANNUAL GENERAL MEETING | - | HKEx | ||
30.04. | IMMUNEONCO-B (01541): CIRCULAR OF THE 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
25.04. | IMMUNEONCO-B (01541): ANNUAL REPORT 2024 | 1 | HKEx | ||
24.04. | IMMUNEONCO-B (01541): NSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE | 2 | HKEx | ||
02.04. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-003/IMM72 | - | HKEx | ||
26.03. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | - | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
ADMA BIOLOGICS | 18,380 | 0,00 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
QIAGEN | 41,150 | -0,19 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
IMMUNOME | 8,790 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 18,090 | 0,00 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report |